Boehringer Ingelheim
For Healthcare Professionals
giotrif

Afatinib-carousel
Afatinib-carousel

Strategies to optimise the management of EGFR TKI-related side effects

01/03/2019  |  Author: Derrick Chen-Wee Aw

An article written by leading oncologists from Singapore containing management strategies which can be helpful in dealing with the TKI-related side effects.

Full article can be accessed at: https://onlinelibrary.wiley.com/doi/10.1111/ajco.12687

clinical oncology image
References & Footnote:
  • 1.
     Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  • 2.
     Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
  • 3.
     Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
  • 4.
    Park K et al. Lancet Oncol 2016;17(5):577–89. 
     EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival.
  • *
    LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).

RELATED CONTENT

What is Afatinib (Giotrif®)?

Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]

*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Afatinib (Giotrif®)?

The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.

References:
  • [1]
     GIOTRIF® Summary of Product Characteristics 2018.
  • [2]
     Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
  • [3]
     Wu YL et al. Lancet Oncol 2014;15(2):213–22.
  • [4]
     Park K et al. Lancet Oncol 2016;17(5):577–89.